Showing results (31-40 of 688) with videos related to
Sort By:
Pageof 69
Biomed Research International|July 19, 2013
Nanocarriers for diagnosis and targeting of breast cancerArun Sharma, Nitin Jain, Rashmi SareenHematology/Oncology Clinics of North America|June 27, 2021
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?Hua-Jay J Cherng, Nitin JainCurrent Drug Delivery|March 29, 2012
An insight to osmotic drug deliveryRashmi Sareen, Nitin Jain, Deepak KumarBMJ Case Reports|January 25, 2013
Plantaris rupture: why is it important?Seema Rohilla, Nitin Jain, Rohtas YadavBlood|April 8, 2014
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLPaolo Strati, Michael J Keating, Susan M O'Brien, et al.Cancer|July 22, 2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensPhilip A Thompson, Susan M O'Brien, William G Wierda, et al.Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.Leukemia|October 22, 2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaMariela Sivina, Lianchun Xiao, Ekaterina Kim, et al.Leukemia & Lymphoma|June 16, 2010
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment optionsApostolia-Maria Tsimberidou, Michael J KeatingCurrent Hematology Reports|December 22, 2004
Treatment of chronic lymphocytic leukemiaStefan J Faderl, Michael J KeatingPageof 69